25,676 results on '"Andrew, To"'
Search Results
2. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
3. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels
4. Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles
5. Risk prediction for clonal cytopenia: multicenter real-world evidence
6. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
7. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
8. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
9. The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
10. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
11. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand
12. Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity
13. Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial
14. The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1β–mediated AML progression
15. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival
16. Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer
17. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population
18. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
19. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
20. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
21. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia
22. How I treat anemia in older adults
23. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
24. Ascorbate deficiency increases quiescence and self-renewal in hematopoietic stem cells and multipotent progenitors
25. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
26. The high-grade B-cell lymphomas: double hit and more
27. Failure of metabolic checkpoint control during late-stage granulopoiesis drives neutropenia in reticular dysgenesis
28. Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy
29. How I treat blastic plasmacytoid dendritic cell neoplasm
30. How I treat patients with AML using azacitidine and venetoclax
31. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
32. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
33. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia
34. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
35. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
36. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress
37. The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants
38. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
39. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
40. Race, rituximab, and relapse in TTP
41. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
42. A signature of platelet reactivity in CBC scattergrams reveals genetic predictors of thrombotic disease risk
43. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
44. LepR+ niche cell–derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging
45. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome
46. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
47. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
48. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events
49. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21
50. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.